News & Trends - MedTech & Diagnostics
Bionic pancreas given breakthrough device designation
Medtech company Beta Bionics has received FDA Breakthrough Device designation for its automated bionic pancreas – the iLet Bionic Pancreas System.
iLet Bionic Pancreas is a wearable, autonomous system that leverages artificial intelligence (AI) and machine learning to deliver insulin and glucagon analogues for treating type 1 diabetes.
The system is designed such that users enter only their body weight for the iLet to initialise therapy. Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.
The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon. The insulin-only and bihormonal configurations may be helpful in diabetes. The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).
Differentiate your business, build thought leadership and boost your network by reaching the Australian Pharma, MedTech and Biotech industry professionals. Health Industry Hub offers unique media solutions to vendors and suppliers servicing the industry. Contact us.
The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogues approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analogue, which has a unique stability profile in a ready-to-use aqueous solution.
Ed Damiano, president and CEO of Beta Bionics, said: “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes. We are particularly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
News & Trends - MedTech & Diagnostics
$54 million cancer centre opens in one of Australia’s fastest growing communities
MedTech & Diagnostics News: Cancer care provider, GenesisCare, is now treating patients at a new $54 million integrated cancer centre […]
MoreMarketing & Strategy
Bayer, MSD and Takeda among winners at Asia Pacific awards
Bayer, MSD, Takeda, Alcon, and Cipla emerge as winners among this week’s announcements of Asia Pacific awards which celebrate organisations […]
MoreNews & Trends - MedTech & Diagnostics
Queensland elevates diagnostic precision with cutting-edge imaging technology
MedTech & Diagnostics News: Mackay Base Hospital and Qscan Mackay have unveiled state-of-the-art medical imaging machines to elevate patient care […]
MoreNews & Trends - Pharmaceuticals
Landmark collaboration sparks inauguration of precision care clinic
Pharma News: In a landmark collaboration, Australians with cancer will receive more personalised care through the newly established Precision Care […]
More